Allogene Therapeutics's quarterly market cap
declined
from Sep. 2024 ($586.60 Mil) to Dec. 2024 ($452.01 Mil) and
declined
from Dec. 2024 ($452.01 Mil) to Mar. 2025 ($319.15 Mil).
Allogene Therapeutics's annual market cap
declined
from Dec. 2022 ($908.52 Mil) to Dec. 2023 ($541.34 Mil) and
declined
from Dec. 2023 ($541.34 Mil) to Dec. 2024 ($452.01 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Allogene Therapeutics's Enterprise Value for Today is $61.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allogene Therapeutics's Market Cap
For the Biotechnology subindustry, Allogene Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Allogene Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (NAS:ALLO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Allogene Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your 